The U.S. Food and Drug Administration recently approved the first available therapeutic treatment for a rare, life-threatening genetic disorder. TAK-755, commercially known as Adzynma, was developed over the past two decades in the laboratory of U-M researcher David Ginsburg. This marks the seventh U-M invention that has secured FDA approval
Dr. Camper's Journal of Clinical Endocrinology & Metabolism paper, Comprehensive identification of pathogenic gene variants in patients with neuroendocrine disorders, was chosen for the Endocrine Society Thematic Issue on
Happy to share our study applying splicing MAVEs to hypopituitarism, out at @AJHGNews https://doi.org/10.1016/j.ajhg.2021.06.013 - a team effort w/former postdoc Peter Gergics in Sally Camper’s lab @UM_Genetics, PhD student in my lab @smithcat1661, and collaborators worldwide.